Terrie Curran - 01 Sep 2022 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
President and Chief Executive, Director
Signature
/s/ Larry Miller, Attorney-in-Fact for Terrie Curran
Issuer symbol
PHAT
Transactions as of
01 Sep 2022
Net transactions value
$0
Form type
4
Filing time
02 Sep 2022, 16:05:35 UTC
Previous filing
03 Jun 2022
Next filing
28 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Award $0 +7,500 +9.6% $0.000000 85,246 01 Sep 2022 Direct F1, F2
holding PHAT Common Stock 2,236 01 Sep 2022 by 401(k) F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Includes 1,151 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022.
F3 Includes 1,511.80 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.